首页> 外文OA文献 >A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
【2h】

A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.

机译:基于重组麻疹病毒疫苗平台的高度免疫原性和保护性中东呼吸综合征冠状病毒疫苗。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

In 2012, the first cases of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) were identified. Since then, more than 1,000 cases of MERS-CoV infection have been confirmed; infection is typically associated with considerable morbidity and, in approximately 30% of cases, mortality. Currently, there is no protective vaccine available. Replication-competent recombinant measles virus (MV) expressing foreign antigens constitutes a promising tool to induce protective immunity against corresponding pathogens. Therefore, we generated MVs expressing the spike glycoprotein of MERS-CoV in its full-length (MERS-S) or a truncated, soluble variant of MERS-S (MERS-solS). The genes encoding MERS-S and MERS-solS were cloned into the vaccine strain MVvac2 genome, and the respective viruses were rescued (MVvac2-CoV-S and MVvac2-CoV-solS). These recombinant MVs were amplified and characterized at passages 3 and 10. The replication of MVvac2-CoV-S in Vero cells turned out to be comparable to that of the control virus MVvac2-GFP (encoding green fluorescent protein), while titers of MVvac2-CoV-solS were impaired approximately 3-fold. The genomic stability and expression of the inserted antigens were confirmed via sequencing of viral cDNA and immunoblot analysis. In vivo, immunization of type I interferon receptor-deficient (IFNAR(-/-))-CD46Ge mice with 2 × 10(5) 50% tissue culture infective doses of MVvac2-CoV-S(H) or MVvac2-CoV-solS(H) in a prime-boost regimen induced robust levels of both MV- and MERS-CoV-neutralizing antibodies. Additionally, induction of specific T cells was demonstrated by T cell proliferation, antigen-specific T cell cytotoxicity, and gamma interferon secretion after stimulation of splenocytes with MERS-CoV-S presented by murine dendritic cells. MERS-CoV challenge experiments indicated the protective capacity of these immune responses in vaccinated mice.
机译:2012年,发现了第一批感染中东呼吸综合征冠状病毒(MERS-CoV)的病例。从那以后,已经确认了1,000多例MERS-CoV感染病例;感染通常与相当高的发病率有关,在大约30%的病例中,与死亡率有关。当前,没有保护性疫苗。具有复制能力的重组麻疹病毒(MV)表达外源抗原构成了诱导针对相应病原体的保护性免疫的有前途的工具。因此,我们产生了在全长(MERS-S)或MERS-S的截短的可溶变异体(MERS-solS)中表达MERS-CoV的突突糖蛋白的MV。将编码MERS-S和MERS-solS的基因克隆到疫苗株MVvac2基因组中,并拯救了各自的病毒(MVvac2-CoV-S和MVvac2-CoV-solS)。这些重组MVs在第3和10代进行了扩增和鉴定。结果证明,Vero细胞中MVvac2-CoV-S的复制与对照病毒MVvac2-GFP(编码绿色荧光蛋白)相当,而MVvac2-的效价却很高。 CoV-solS受损约3倍。通过病毒cDNA的测序和免疫印迹分析证实了基因组稳定性和插入抗原的表达。在体内,用2×10(5)50%组织培养感染剂量的MVvac2-CoV-S(H)或MVvac2-CoV-solS免疫I型干扰素受体缺陷型(IFNAR(-/-))-CD46Ge小鼠(H)在初免-加强方案中诱导了MV-和MERS-CoV中和抗体的稳定水平。此外,鼠类树突状细胞呈递的MERS-CoV-S刺激脾细胞后,T细胞增殖,抗原特异性T细胞细胞毒性和γ干扰素分泌证明了特异性T细胞的诱导。 MERS-CoV攻击实验表明这些免疫应答在接种小鼠中具有保护能力。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号